Cargando…

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts

Glioblastoma multiforme (GBM) is at present an incurable disease with a 5-year survival rate of 5.5%, despite improvements in treatment modalities such as surgery, radiation therapy, chemotherapy [e.g., temozolomide (TMZ)], and targeted therapy [e.g., the antiangiogenic agent bevacizumab (BEV)]. Dif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishri, Yossi, Vatarescu, Maayan, Luz, Ishai, Epstein, Lior, Dumančić, Mirta, Del Mare, Sara, Shai, Amit, Schmidt, Michael, Deutsch, Lisa, Den, Robert B., Kelson, Itzhak, Keisari, Yona, Arazi, Lior, Cooks, Tomer, Domankevich, Vered
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552201/ https://www.ncbi.nlm.nih.gov/pubmed/36237307 http://dx.doi.org/10.3389/fonc.2022.888100

Ejemplares similares

Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response
por: Domankevich, Vered, et al.
Publicado: (2019)

RIG-1-Like Receptor Activation Synergizes With Intratumoral Alpha Radiation to Induce Pancreatic Tumor Rejection, Triple-Negative Breast Metastases Clearance, and Antitumor Immune Memory in Mice
por: Domankevich, Vered, et al.
Publicado: (2020)

The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules
por: Keisari, Yona, et al.
Publicado: (2021)

Extracellular vesicles: what secrets do they hold inside?
por: Luz, Ishai, et al.
Publicado: (2019)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
por: Toren, Amos, et al.
Publicado: (2016)

HGG-04. ZINC ENHANCES TEMOZOLOMIDE CYTOTOXICITY IN PEDIATRIC GLIOBLASTOMA MULTIFORME MODEL SYSTEM
por: Toren, Amos, et al.
Publicado: (2020)

A New Approach for a Safe and Reproducible Seeds Positioning for Diffusing Alpha-Emitters Radiation Therapy of Squamous Cell Skin Cancer: A Feasibility Study
por: Feliciani, Giacomo, et al.
Publicado: (2022)

Clinical evidence of abscopal effect in cutaneous squamous cell carcinoma treated with diffusing alpha emitters radiation therapy: a case report
por: Bellia, Salvatore Roberto, et al.
Publicado: (2019)

Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
por: Faustino, Alexandre Ciuffi, et al.
Publicado: (2020)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Cancer Cells Shuttle Extracellular Vesicles Containing Oncogenic Mutant p53 Proteins to the Tumor Microenvironment
por: Bhatta, Bibek, et al.
Publicado: (2021)

Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide
por: Gebhardt, Brian J, et al.
Publicado: (2014)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting—Ideal Versus Reality
por: Lee, Chooi Yeng, et al.
Publicado: (2016)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
por: Heynckes, Sabrina, et al.
Publicado: (2019)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
por: Yung, W K A, et al.
Publicado: (2000)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
por: Aherne, Noel J., et al.
Publicado: (2014)

Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment
por: Jakubowicz-Gil, Joanna, et al.
Publicado: (2013)

Elimination of Cancer Stem-Like Cells and Potentiation of Temozolomide Sensitivity by Honokiol in Glioblastoma Multiforme Cells
por: Lai, I-Chun, et al.
Publicado: (2015)

In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme
por: Borhani, Samira, et al.
Publicado: (2017)

Temozolomide in Combination With NF-κB Inhibitor Significantly Disrupts the Glioblastoma Multiforme Spheroid Formation
Publicado: (2020)

Glutathione S-Transferase M3 Is Associated with Glycolysis in Intrinsic Temozolomide-Resistant Glioblastoma Multiforme Cells
por: Cheng, Shu-Yu, et al.
Publicado: (2021)

Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide
por: Feng, Shao-Wei, et al.
Publicado: (2023)

Downregulation of the inflammatory network in senescent fibroblasts and aging tissues of the long‐lived and cancer‐resistant subterranean wild rodent, Spalax
por: Odeh, Amani, et al.
Publicado: (2019)

Cavity ring-up spectroscopy for ultrafast sensing with optical microresonators
por: Rosenblum, Serge, et al.
Publicado: (2015)

Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry
por: Braun, Klaus, et al.
Publicado: (2009)

3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors
por: Tezcan, Yilmaz, et al.
Publicado: (2011)

Prospective study evaluating the radiosensitizing effect of reduced doses of temozolomide in the treatment of Egyptian patients with glioblastoma multiforme
por: Gaber, May, et al.
Publicado: (2013)

Effects of combined radiosurgery and temozolomide therapy on epidermal growth factor receptor and variant III in glioblastoma multiforme
por: Lin, Yiguang, et al.
Publicado: (2018)

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial
por: Marinelli, Alfredo, et al.
Publicado: (2018)

Temozolomide and tranilast synergistic antiproliferative effect on human glioblastoma multiforme cell line (U87MG)
por: Khazaei, Mozafar, et al.
Publicado: (2019)

Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells
por: Cheng, Quan, et al.
Publicado: (2017)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
por: Alimohammadi, Ehsan, et al.
Publicado: (2020)

Histone 2A Family Member J Drives Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Multiforme
por: Lee, Hsun-Hua, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3joac54gv6do6c2g9aplm9d7bn